Eli Lilly’s Omvoh Meets Primary Endpoint in Pediatric Ulcerative Colitis Trial

The pediatric readout extends Omvoh's clinical narrative beyond the adult population where it was first established, which matters for a drug still building out its label. The disclosure is thin, though: a met primary endpoint without effect sizes, safety data or the specific endpoint measure leaves the practical significance unresolved. For Lilly, the near-term question is whether the full dataset supports a regulatory path in this younger population, and whether the tolerability profile holds up in children. Until those details surface, the headline signals momentum rather than a settled case.